Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05760378 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05760378 · ClinicalTrials.gov record · last posted 2024-02-06

Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

StatusRecruiting
PhasePhase 3
Started2023-03-17
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 6, 2024 (before its estimated January 1, 2025 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
The study is being conducted to evaluate the Famitinib with Camrelizumab plus treatment of physician's choice (TPC) versus Camrelizumab plus TPC in Patients with Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer.

Amendment record 3 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 3 times since 2023-02-27; most recent amendment 2024-02-04. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2023-03-26
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT05760378
Lead Sponsor Fudan University
Conditions Triple-Negative Breast Cancer
Enrollment 223 participants
Start Date 2023-03-17
Primary Completion 2025-01-01 (estimated)
Study Completion 2027-01-01 (estimated)
Updated on ClinicalTrials.gov 2024-02-06